Abstract:Background: Although many treatments for breast cancer are available, poor tumour targeting limits the effectiveness of most approaches. Consequently, it is difficult to achieve satisfactory results with monotherapies. The lack of accurate diagnostic and monitoring methods also limit the benefits of cancer treatment. The aim of this study was to design a nanocarrier comprising porous gold nanoshells (PGNSs) co-decorated with methoxy polyethylene glycol (mPEG) and trastuzumab (Herceptin®, HER), a therapeutic monoclonal antibody that binds specifically to human epidermal receptor-2 (HER2)-overexpressing breast cancer cells. Furthermore, a derivative of the microtubule-targeting drug maytansine (DM1) was incorporated in the PGNSs. Methods: Prepared PGNSs were coated with mPEG, DM1 and HER via electrostatic interactions and Au-S bonds to yield DM1-mPEG/HER-PGNSs. SK-BR-3 (high HER2 expression) and MCF-7 (low HER2) breast cancer cells were treated with DM1-mPEG/HER-PGNSs, and cytotoxicity was evaluated in terms of cell viability and apoptosis. The selective uptake of the coated PGNSs by cancer cells and subsequent intracellular accumulation were studied in vitro and in vivo using inductively coupled plasma mass spectrometry and fluorescence imaging. The multimodal imaging feasibility and synergistic chemo-photothermal therapeutic efficacy of the DM1-mPEG/HER-PGNSs were investigated in breast cancer tumour-bearing mice. The molecular mechanisms associated with the anti-tumour therapeutic use of the nanoparticles were also elucidated. Result: The prepared DM1-mPEG/HER-PGNSs had a size of 78.6 nm and displayed excellent colloidal stability, photothermal conversion ability and redox-sensitive drug release. These DM1-mPEG/HER-PGNSs were taken up selectively by cancer cells in vitro and accumulated at tumour sites in vivo. Moreover, the DM1-mPEG/HER-PGNSs enhanced the performance of multimodal computed tomography (CT), photoacoustic (PA) and photothermal (PT) imaging and enabled chemo-thermal combination therapy. The therapeutic mechanism involved the induction of tumour cell apoptosis via the activation of tubulin, caspase-3 and the heat shock protein 70 pathway. M2 macrophage suppression and anti-metastatic functions were also observed. Conclusion: The prepared DM1-mPEG/HER-PGNSs enabled nanodart-like tumour targeting, visibility by CT, PA and PT imaging in vivo and powerful tumour inhibition mediated by chemo-thermal combination therapy in vivo. In summary, these unique gold nanocarriers appear to have good potential as theranostic nanoagents that can serve both as a probe for enhanced multimodal imaging and as a novel targeted anti-tumour drug delivery system to achieve precision nanomedicine for cancers.

Preparation of herceptin-gold nanoprobe and its inhibitory effect on breast cancer cells

Radiosensitizer-based Injectable Hydrogel for Enhanced Radio-Chemotherapy of TNBC

Her2-Targeted Multifunctional Nano-Theranostic Platform Mediates Tumor Microenvironment Remodeling and Immune Activation for Breast Cancer Treatment

Cytotoxicity analysis of gold nanorods conjugated with dual-target inhibitors on humant-riple negative breast cancer cell

Inhibition of HER2‐Positive Breast Cancer Growth by Blocking the HER2 Signaling Pathway with HER2‐Glycan‐Imprinted Nanoparticles

Preparation and Characterization of PE38KDEL-loaded Anti-Her2 Nanoparticles for Targeted Cancer Therapy

Her2-Functionalized Gold-Nanoshelled Magnetic Hybrid Nanoparticles: a Theranostic Agent for Dual-Modal Imaging and Photothermal Therapy of Breast Cancer

Hyaluronidase Responsive Second Near-Infrared Fluorescent Nanocomplex for Combined HER2 Blockade and Chemotherapy of HER2+ Breast Cancer

Multicomponent delivery system based on biologically produced gold nanoparticles for targeted therapy of breast cancer in vivo

Preparation and targeting study of Herceptin loaded PLGA-COOH-targeted ultrasound contrast agent

Enhanced Delivery of Paclitaxel Using Electrostatically-Conjugated Herceptin-bearing PEI/PLGA Nanoparticles Against HER-positive Breast Cancer Cells.

Herceptin-Conjugated DOX-Fe3O4/P(NIPAM-AA-MAPEG) Nanogel System for HER2-Targeted Breast Cancer Treatment and Magnetic Resonance Imaging

[Novel HER2-Targeted Therapy Combined with Gold Nanoparticles]

The in Vitro Study of Her-2 Targeted Gold Nanoshell Liquid Fluorocarbon Poly Lactic-Co-glycolic Acid Ultrasound Microcapsule for Ultrasound Imaging and Breast Tumor Photothermal Therapy.

Biological evaluation of a novel Herceptin-platinum (II) conjugate for efficient and cancer cell specific delivery

Herceptin-Conjugated DOX-Fe 3 O 4 /P(NIPAM-AA-MAPEG) Nanogel System for HER2-Targeted Breast Cancer Treatment and Magnetic Resonance Imaging

A Multifunctional Bimetallic Nanoplatform for Synergic Local Hyperthermia and Chemotherapy Targeting HER2-Positive Breast Cancer

Targeted gold nanoshelled hybrid nanocapsules encapsulating doxorubicin for bimodal imaging and near-infrared triggered synergistic therapy of Her2-positve breast cancer.

A DM1-doped porous gold nanoshell system for NIR accelerated redox-responsive release and triple modal imaging guided photothermal synergistic chemotherapy

Monoclonal-Antibody-Templated Gold Nanoclusters for HER2 Receptors Targeted Fluorescence Imaging

Antibody-drug nanoparticle induces synergistic treatment efficacies in HER2 positive breast cancer cells